Can a lab technique mature eggs more gently for IVF?
NCT ID NCT07789730
First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time
Summary
This pilot trial tests CAPA-IVM, a two-step laboratory process that matures eggs after they are retrieved, as an option for people with good ovarian reserve who need fertility treatment. Researchers will check how many eggs reach maturity, how many fertilize, and whether the method is practical. The study includes about 40 participants aged 18 to 37 with healthy egg supply. The goal is to see if this approach can support pregnancy with less hormone stimulation.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CAPA-IVM, a two-step laboratory process to mature eggs after retrieval
- What this could lead to
- If it works, CAPA-IVM could offer a gentler, hormone-sparing way to mature eggs in the lab and help more people with good ovarian reserve achieve pregnancy.
- What could go wrong
- This is a small pilot study, so success is not guaranteed. The approach may not improve pregnancy rates, and risks include fertilization or embryo development issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2026
- Expected to finish
-
Feb 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 37 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Signed Informed Consent Form to participate in this study voluntarily. 2. Age 18-37 years at the time of starting the CAPA-IVM cycle. 3. Body mass index (BMI) ≤38 kg/m2. 4. Serum AMH levels greater than or equal to 3.5 ng/mL. 5. Have an indication for IVM/IVF cycle. 6. Have not received more than two previous treatments of IVM/IVF. 7. Willing and able to comply with trial procedures, including oocyte pick-up from small follicles and to follow a CAPA-IVM cycle. 8. Agree to culture all embryos to blastocyst stage, vitrify suitable blastocysts, and submit suitable blastocysts for PGT-A according to clinic protocol before determining transfer eligibility. 9. Agree that only euploid CAPA-IVM-derived blastocysts will be eligible for transfer and that a single euploid blastocyst will be transferred per programmed FET cycle, unless a protocol-defined exception is prospectively justified by the investigator. Exclusion Criteria: 1. Prior ovarian surgery. 2. Known uterine abnormalities (adenomyosis, leiomyoma (≥5 cm), bicornuate uterus, intrauterine adhesion) that would compromise successful pregnancy or live birth. 3. Had received ovarian stimulation within the last 3 months for ovulation induction or IVF 4. Had evidence of a very low oocyte maturation rate (oocyte maturation rate \< 50% in any previous IVF or IVM cycle). 5. For male partners: severe oligoasthenoteratozoospermia, requirement for retrograde ejaculation procedures or surgical sperm retrievals. Donor sperm is permitted. 6. Known chromosomal abnormalities in participant or partner. 7. Have herself or partner with acute urinary tract infection or sexually transmitted diseases. 8. Have herself or partner a severe mental disorder, such as schizophrenia, bipolar affective disorder, or intellectual disability caused by mental disorders. 9. Have a history of recurrent pregnancy loss defined as two or more clinical pregnancies without live birth. 10. Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus that would preclude to conduct a CAPA-IVM cycle without ovarian stimulation or participation in this study. 11. Any known clinically significant systemic disease (heart, liver, kidney or other organs) that would prevent or compromise pregnancy or participation in this study. 12. Pregnancy or contraindication to pregnancy. 13. Undiagnosed vaginal bleeding. 14. Known drug or alcohol abuse or dependency for the participant or partner for the last 12 months. 15. Current or past (3 months) smoking habit of 10 or more cigarettes per day. 16. Had a recent exposure to teratogenic radiation, drugs or toxins which could still be active during the study period. 17. Currently participating in another clinical trial or receiving an investigational medicinal product. 18. Previous participation in this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Assisted reproduction technologies are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Aspire Fertility Houston
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a lighter touch in IVF yield healthier embryos for women over 35?
- Can a simpler fertility drug dose match the standard for IUI success?
- A Hormone-Free IVF path? Lab-Matured eggs put to the test
- Can a fertility drug's safety be tracked in real-world use?
- Can a suppository or a local block take the pain out of fertility testing?
- Could a simple ultrasound replace blood tests for fertility?